Isis reaches new highs on Phase I SMA drug data
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals has seen its fair share of stock price gains this year and the company closed up another 14.1% to reach a new high of $36.27 per share on 19 September on the news that children with spinal muscular atrophy in a Phase I study continued to show benefits up to 14 months after a single intrathecal injection with the two highest doses of ISIS-SMNRx.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.